Stocks · News reference
Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Buy rating and announces Price Target of $70.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Quince Therapeutics has rebranded to IRulya Therapeutics and will trade on Nasdaq under ticker 'IRLA' starting October 12, 2026. The company is focused on advancing LAM-001, an inhaled rapamycin formulation for pulmonary diseases including PH-ILD, BOS, and SAPH. New leadership has been appointed including CEO Brigette Roberts, M.D., and the company has a cash balance of $116 million expected to fund operations through end of 2028.
Quince Therapeutics Announces Appointment Of Brigette Roberts As CEO, John Militello As CFO, And Keith Fandrick As COO; CEO Dirk Thye And COO Brendan Hannah Resign
Quince Therapeutics Announces Name Change To IRulya Therapeutics And Nasdaq Ticker Change From QNCX To IRLA, Effective October 12